Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01218555 · ClinicalTrials.gov registry record · Phase 1
Study of Everolimus (RAD001) in Combination With Lenalidomide
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT01218555 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 44 participants.
The verdict
NCT01218555, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to study the combination of two anticancer drugs, everolimus (RAD001) and lenalidomide in patients whose cancer is no longer responding to standard treatment or patients who are unable to tolerate the standard treatment for their cancer.
Interventions
- DRUG Everolimus
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2010-09-09 |
| Est. Completion | 2020-11-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01218555
The ClinicalTrials.gov registry entry for NCT01218555 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT01218555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01218555 about?
NCT01218555 is a clinical study titled "Study of Everolimus (RAD001) in Combination With Lenalidomide". The purpose of this study is to study the combination of two anticancer drugs, everolimus (RAD001) and lenalidomide in patients whose cancer is no longer responding to standard treatment or patients who are unable to tolerate the standard treatment for their cancer.
What is the current status of trial NCT01218555?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2010-09-09. Estimated completion is 2020-11-05.
What interventions are being tested in trial NCT01218555?
The interventions under investigation include: Everolimus (DRUG), Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01218555?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.